Tüdőrák: nyitott vizsgálatok itt: Kolumbia
23 trials · From ClinicalTrials.gov, checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- Where
- Bogotá, Cali, Medellín, Pereira, Valledupar
- Age
- 18 év and over
- People
- 1000 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06561386EU 2024-513682-40-01Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Bogotá, Cali, Montería, Pereira
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422EU 2023-506327-29-00Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Where
- Bogota, Bogotá, Medellín, Montería, Rionegro
- Age
- 18 év and over
- People
- 876 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07513376EU 2025-522643-18-00Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Where
- Barranquilla, Bogota, D.C., Florindablanca, Medellín
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07541170EU 2025-524263-21-01Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Barranquilla, Bogota, Bucaramanga, Cali, Medellín, Montería, Pereira, Valledupar
- Age
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356EU 2022-501863-41-00Regiszter frissítve: 2026-11-06
3. fázisToborozTrial-stage medicine
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Where
- Bogotá, Montería, Pereira
- Age
- 18 év and over
- People
- 614 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06170788EU 2023-503376-24-00Regiszter frissítve: 2026-11-03
3. fázisToborozTrial-stage medicine
MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Bogota, Bogotá, Medellín, Montería, Pereira
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827EU 2024-517337-41-00Regiszter frissítve: 2026-11-02
2/3. fázisToborozTrial-stage medicine
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Bogotá, Floridablanca, Medellín, Montería, Valledupar
- Age
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596EU 2023-508922-83-00Regiszter frissítve: 2026-10-30
3. fázisToborozTrial-stage medicine
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Bogotá, Medellín, Montería, Valledupar
- Age
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846EU 2023-505749-14-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
- Where
- Barranquilla, Bogotá, Cali, Pereira, Valledupar
- Age
- 18 év and over
- People
- 851 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06422143EU 2023-510128-66-00Regiszter frissítve: 2026-10-29
3. fázisToborozTrial-stage medicine
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Cali, Floridablanca, Medellín, Montería, Rionegro, Valledupar
- Age
- 18 év and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310EU 2024-515698-85-00Regiszter frissítve: 2026-10-27
3. fázisToborozTrial-stage medicine
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Bogota, Cali, Pereira, Valledupar
- Age
- 18 év and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729EU 2023-507776-42-00Regiszter frissítve: 2026-10-26
3. fázisToborozTrial-stage medicine
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Bogotá, Medellín
- Age
- 18 év and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248EU 2024-514500-14-00Regiszter frissítve: 2026-10-26
2/3. fázisToborozTrial-stage medicine
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Bogotá, Medellín, Montería
- Age
- 18 év and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745EU 2025-521511-40-00Regiszter frissítve: 2026-10-23
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Barranquilla, Bogotá, Medellín, Rionegro
- Age
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510EU 2025-523586-18-00Regiszter frissítve: 2026-10-23
2/3. fázisToborozTrial-stage medicine
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Bogotá, Cali, Montería, Valledupar
- Age
- 18 év and over
- People
- 500 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080Regiszter frissítve: 2026-10-09
3. fázisToborozTrial-stage medicine
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- Where
- Cali, Floridablanca, Medellín, Valledupar
- Age
- 18 év and over
- People
- 830 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06868277EU 2024-517780-24-00Regiszter frissítve: 2026-09-25
No phaseToborozResearch participation
Guaraná Supplementation for Cancer-Related Fatigue
- Where
- Bogotá
- Age
- 18 év and over
- People
- 60
- Run by
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
See details and how to joinNCT07816263Regiszter frissítve: 2026-09-11
No phaseToborozResearch participation
Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia
- Where
- Bogotá
- Age
- 18 év and over
- People
- 3250
- Run by
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
See details and how to joinNCT07741435Regiszter frissítve: 2026-08-03
No phaseToborozResearch participation
Characterization, Health Resource Utilization and Biomarkers in Early-stage
- Where
- Bogotá
- Age
- 18 év to 80 év
- People
- 267
- Run by
- Hospital Universitario San Ignacio
See details and how to joinNCT07703631Regiszter frissítve: 2026-07-14
No phaseToborozResearch participation
Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib
- Where
- Bogota
- Age
- 18 év and over
- People
- 24
- Run by
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
See details and how to joinNCT07633626Regiszter frissítve: 2026-06-08
No phaseToborzás még nem indultResearch participation
Lung Cancer Screening for Early Detection of Suspicious Lung Nodules in Latin America(LUCAS-LATAM)
- Where
- Bogotá
- Age
- 50 év and over
- People
- 2000 worldwide
- Run by
- Latin American Consortium for the Lung Cancer Research
See details and how to joinNCT07524803Regiszter frissítve: 2026-04-13
No phaseToborzás még nem indultResearch participation
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)
- Where
- Bogotá
- Age
- 18 év to 99 év
- People
- 35
- Run by
- Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
See details and how to joinNCT05998993Regiszter frissítve: 2023-08-21
Minden vizsgálat (Tüdőrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.